AnteoTech has announced that its EuGeni Reader and accompanying COVID-19 Antigen Rapid Test (ART) have received CE-mark registration as the company looks to progress with European distribution.
The digital multi-test EuGeni Reader eliminates the human error associated with current lateral-flow test interpretation, and can support high-sensitivity quantitative readouts for time-critical disease and clinical intervention tracking.
The COVID-19 ART boasts exceptional sensitivity and specificity, and delivers test results in less than 15 minutes. As such, it will be a key tool to support efficient frontline screening as economies look to reopen across the continent. A first-of-its-kind, ultrahigh-sensitivity COVID-19 saliva test is the next of a suite of tests being developed for the EuGeni Reader, overcoming the poor sensitivity of currently available saliva-based COVID-19 tests.
AnteoTech’s EuGeni platform is a highly interactive, user-friendly reader system underpinned by patented AnteoBind nanoparticle technology, offering exceptional test sensitivity and specificity. The first test to use the platform – AnteoTech’s COVID-19 ART – has demonstrated 97.3% sensitivity and 99.6% specificity in clinical studies, enables on-the-spot identification of persons with suspected SARS-CoV-2 infection, and can be processed at 60 tests per hour using the EuGeni Reader. Such capabilities make it an unmatched solution for swift mass screening in critical industries, including healthcare, public events and travel.